Results 61 to 70 of about 142 (121)

Rezafungin Utilisation in Real Life—FungiScope Results From Europe and the United States

Mycoses, Volume 68, Issue 9, September 2025.
ABSTRACT Background Rezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real‐world experience remains limited.
Ilana Reinhold, Giovanni Mori, Massimiliano Lanzafame, Alessandro Limongelli, Antonio Vena, Julia Götz, Stilla Bauernfeind, Frank Hanses, Lukas Tometten, Michael Mayer, Ansgar Rieke, Ana Soriano‐Martin, Maricela Valerio, Jose A. Vazquez, Patrick Yue, Laman Rahimli, Nijat Azimli, Ertan Sal, Jon Salmanton‐García, Natalia Vasenda, Rosanne Sprute, Jannik Stemler, Sebastian Wingen‐Heimann, Oliver A. Cornely, Danila Seidel   +24 more
wiley   +1 more source

Virulence and resistance factors of Nakaseomyces glabratus (formerly known as Candida glabrata) in Europe: A systematic review

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 2, Page 377-388, February 2025.
Nakaseomyces glabratus (formerly known as Candida glabrata) is an endogenous opportunistic pathogen that causes various clinical manifestations, ranging from mucocutaneous overgrowth to bloodstream infections. This review aims to summarize the biology, epidemiology and pathology of N.
Carmen Rodríguez‐Cerdeira, Rodolfo Pinto‐Almazán, Ditte M. L. Saunte, R. Hay, Jacek C. Szepietowski, Gabriela Moreno‐Coutiño, Mihael Skerlev, Asja Prohic, Erick Martínez‐Herrera   +8 more
wiley   +1 more source

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Archiv der Pharmazie, Volume 358, Issue 1, January 2025.
This review presents 17 macrocyclic drugs approved by the U.S. Food and Drug Administration during the past 5 years, highlighting their importance and critical role in modern therapeutics, and the innovative synthetic approaches for the construction of these macrocycles.
Youlong Du, Anas Semghouli, Qian Wang, Haibo Mei, Loránd Kiss, Daniel Baecker, Vadim A. Soloshonok, Jianlin Han   +7 more
wiley   +1 more source

Real-world experience with rezafungin for the treatment of biofilm-forming Candida infections

Future Microbiology
Biofilm eradication remains a significant challenge in clinical practice and contributes substantially to healthcare costs. Medical devices serve as a common substrate for biofilm formation and are implicated in a considerable proportion of invasive candidiasis cases.
Marta Albanell-Fernández, Álex Soriano, Sabina Herrera, Montse Tuset, Natalia Arranz, Corentin Deckers, Patrick M Honoré   +6 more
openaire   +4 more sources

Clinical Case Report on the Use of Rezafungin in Pneumocystis jirovecii Pneumonia in a Critically Ill Patient

Microorganisms
Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection predominantly affecting immunocompromised patients. Trimethoprim–sulfamethoxazole (TMP–SMX) remains the standard therapy but is often limited by severe toxicity ...
Rosario Fernández-Fernández, Roberto García-Martínez, Waldo Sánchez-Yebra Fernández, Natalia Chueca-Porcuna, Manuel Colmenero-Ruiz   +4 more
doaj   +1 more source

Lactams Exhibit Potent Antifungal Activity Against Monospecies and Multispecies Interkingdom Biofilms on a Novel Hydrogel Skin Model

APMIS, Volume 133, Issue 1, January 2025.
ABSTRACT Infections of intact and damaged skin barriers and keratin are frequently associated with complex biofilm communities containing bacteria and fungi, yet there are limited options for successful management. This study intended to focus on the utility of some novel proprietary lactam molecules, quorum sensing (QS)–derived halogenated furanones ...
Hafsa Abduljalil, Om Alkhir Alshanta, Safa Chougule, Mark Butcher, Bryn Short, William McLean, Neil Parry, Joanne O'Keeffe, Gordon Ramage   +8 more
wiley   +1 more source

Necrotizing gingival infection due to in an hematopoietic stem cell transplant recipient: case report

Therapeutic Advances in Infectious Disease
Trichoderma is a genus of rare filamentous fungi that can cause invasive fungal infections in immunocompromised patients. We report a case of necrotizing gingival and sinus infection due to T.
Eduardo Aparicio-Minguijón, Nieves López-Muñoz, Pilar Martínez-Sánchez, María Calbacho, Ana Pérez-Ayala, Justino Jiménez-Almonacid, María Asunción Pérez-Jacoiste Asín, Isabel Rodríguez-Goncer   +7 more
doaj   +1 more source

Successful treatment with rezafungin after micafungin for relapsing Rasamsonia argillacea species complex pneumonia in a patient with bronchiectasis: A case report

International Journal of Infectious Diseases
Rasamsonia argillacea species complex are emerging opportunistic molds increasingly reported in patients with chronic lung disease. We describe a 69-year-old woman with bronchiectasis who developed relapsing R. aegroticola pneumonia.
Hugo Bes-Berlandier, Noémie Coron, Heloise Pottier, Sabrina Manni, Coline Mortier, Jean Philippe Bouchara, Coralie Barrera, Anne-Pauline Bellanger-Clerget, Laurence Millon, Perrine Parize, Fanny Lanternier, Olivier Lortholary, Julien Bermudez, Nadim Cassir, Benjamin Coiffard   +14 more
doaj   +1 more source

The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies

Chemical Biology &Drug Design, Volume 105, Issue 1, January 2025.
The future of treating challenging fungal infections lies in novel therapies targeting new antifungal targets, overcoming resistance mechanisms, and exploring innovative dual inhibitors. ABSTRACT Invasive fungal infections (IFIs) pose significant challenges in clinical settings, particularly due to their high morbidity and mortality rates.
Cengiz Zobi, Oztekin Algul
wiley   +1 more source

A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin

Journal of Fungi
This mini-review summarizes the clinical outcomes and antifungal susceptibility results, where available, for three new antifungals, including fosmanogepix, ibrexafungerp, and rezafungin, against Candida isolates cultured from patients in clinical trials.
Ana Espinel-Ingroff, Nathan P. Wiederhold   +1 more
doaj   +1 more source